|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics. CA Cancer J Clin.
58:71–96. 2008.
|
|
2
|
Hori S, Nomura T and Sakaguchi S: Control
of regulatory T cell development by the transcription factor Foxp3.
Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fontenot JD, Rasmussen JP, Williams LM,
Dooley JL, Farr AG and Rudensky AY: Regulatory T cell lineage
specification by the forkhead transcription factor Foxp3. Immunity.
22:329–341. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Woo EY, Yeh H, Chu CS, Schlienger K,
Carroll RG, Riley JL, Kaiser LR and June CH: Cutting edge:
regulatory T cells from lung patients directly inhibit autologous T
cell proliferation. J Immunol. 168:4272–4276. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schneider T, Kimpfler S, Warth A, Schnabel
PA, Dienemann H, Schadendorf D, Hoffmann H and Umansky V:
Foxp3+ regulatory T cells and killer cells distinctly
infiltrate primary tumors and draining lymph nodes in pulmonary
adenocarcinoma. J Thorac Oncol. 6:432–438. 2011.
|
|
6
|
Shimizu K, Nakata M, Hirami Y, Yukawa T,
Maeda A and Tanemoto K: Tumor-infiltrating Foxp3+
regulatory T cells are correlated with cyclooxygenase-2 expression
and are associated with recurrence in resected non-small cell lung
cancer. J Thorac Oncol. 5:585–590. 2010.
|
|
7
|
Tokuno K, Hazama S, Yoshino S, Yoshida S
and Oka M: Increased prevalence of regulatory T-cells in the
peripheral blood of patients with gastrointestinal cancer.
Anticancer Res. 29:1527–1532. 2009.PubMed/NCBI
|
|
8
|
Deng L, Zhang H, Luan Y, Zhang J, Xing Q,
Dong S, Wu X, Liu M and Wang S: Accumulation of foxp3+ T
regulatory cells in draining lymph nodes correlates with disease
progression and immune suppression in colorectal cancer patients.
Clin Cancer Res. 16:4105–4112. 2010.
|
|
9
|
Petersen RP, Campa MJ, Sperlazza J, et al:
Tumor infiltrating Foxp3+ regulatory T-cells are
associated with recurrence in pathologic stage I NSCLC patients.
Cancer. 107:2866–2872. 2006.PubMed/NCBI
|
|
10
|
Hinz S, Pagerols-Raluy L, Oberg HH, et al:
Foxp3 expression in pancreatic carcinoma cells as a novel mechanism
of immune evasion in cancer. Cancer Res. 67:8344–8350. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zuo T, Liu R, Zhang H, Chang X and Liu Y,
Wang L, Zheng P and Liu Y: FOXP3 is a novel transcriptional
repressor for the breast cancer oncogene SKP2. J Clin Invest.
117:3765–3773. 2007.PubMed/NCBI
|
|
12
|
Merlo A, Casalini P, Carcangiu ML,
Malventano C, Triulzi T, Mènard S, Tagliabue E and Balsari A: FOXP3
expression and overall survival in breast cancer. J Clin Oncol.
27:1746–1752. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang LH, Su L and Wang JT: Correlation
between elevated FOXP3 expression and increased lymph node
metastasis of gastric cancer. Chin Med J (Engl). 123:3545–3549.
2010.PubMed/NCBI
|
|
14
|
Wang G, Liu G, Liu Y, Li X and Su Z: FOXP3
expression in esophageal cancer cells is associated with poor
prognosis in esophageal cancer. Hepatogastroenterology. 59:Mar
2–2012.(Epub ahead of print). View
Article : Google Scholar
|
|
15
|
Szczepanski MJ, Szajnik M, Czystowska M,
et al: Increased frequency and suppression by regulatory T cells in
patients with acute myelogenous leukemia. Clin Cancer Res.
15:3325–3332. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu H, Mao Y, Dai Y, Wang Q and Zhang X:
CD4+CD25+ regulatory T cells in patients with
advanced gastrointestinal cancer treated with chemotherapy.
Onkologie. 32:246–252. 2009.
|
|
17
|
Ruan Q, Kameswaran V, Tone Y, Li L, Liou
HC, Greene MI, Tone M and Chen YH: Development of Foxp3+
regulatory T cells is driven by A c-Rel enhanceosome. Immunity.
31:932–940. 2009.PubMed/NCBI
|
|
18
|
Melaine N, Liénard MO, Dorval I, Le
Goascogne C, Lejeune H and Jégou B: Multidrug resistance genes and
p-glycoprotein in the testis of the rat, mouse, Guinea pig, and
human. Biol Reprod. 67:1699–1707. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Simeone L, Straubinger M, Khan MA,
Nalleweg N, Cheusova T and Hashemolhosseini S: Identification of
Erbin interlinking MuSK and ErbB2 and its impact on acetylcholine
receptor aggregation at the neuromuscular junction. J Neurosci.
30:6620–6634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shim GS, Manandhar S, Shin DH, Kim TH and
Kwak MK: Acquisition of doxorubicin resistance in ovarian carcinoma
cells accompanies activation of the NRF2 pathway. Free Radic Biol
Med. 47:1619–1631. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Widmer N, Colombo S, Buclin T and
Decosterd LA: Functional consequence of MDR1 expression on imatinib
intracellular concentrations. Blood. 102:11422003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Aller SG, Yu J, Ward A, et al: Structure
of P-glycoprotein reveals a molecular basis for poly-specific drug
binding. Science. 323:1718–1722. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Loo TW and Clarke DM: Location of the
rhodamine-binding site in the human multidrug resistance
P-glycoprotein. J Biol Chem. 277:44332–44338. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ambudkar SV, Kim IW and Sauna ZE: The
power of the pump: mechanisms of action of P-glycoprotein (ABCB1).
Eur J Pharm Sci. 27:392–400. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Szachowicz-Petelska B, Figaszewski Z and
Lewandowski W: Mechanisms of transport across cell membranes of
complexes contained in antitumour drugs. Int J Pharm. 222:169–182.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pires MM, Emmert D, Hrycyna CA and
Chmielewski J: Inhibition of P-glycoprotein-mediated paclitaxel
resistance by reversibly linked quinine homodimers. Mol Pharmacol.
75:92–100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Enokida H, Gotanda T, Oku S, et al:
Reversal of P-glycoprotein mediated paclitaxel resistance by new
synthetic isoprenoids in human bladder cancer cell line. Jpn J
Cancer Res. 93:1037–1046. 2002. View Article : Google Scholar : PubMed/NCBI
|
